169 related articles for article (PubMed ID: 36968952)
1. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).
Sader HS; Castanheira M; Kimbrough JH; Kantro V; Mendes RE
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad032. PubMed ID: 36968952
[TBL] [Abstract][Full Text] [Related]
2. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
[TBL] [Abstract][Full Text] [Related]
3. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE
J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387
[TBL] [Abstract][Full Text] [Related]
4. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Castanheira M
Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):477-487. PubMed ID: 35041100
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] [Abstract][Full Text] [Related]
7. In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant
Zou C; Wei J; Shan B; Chen X; Wang D; Niu S
Infect Drug Resist; 2020; 13():3563-3568. PubMed ID: 33116675
[TBL] [Abstract][Full Text] [Related]
8.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
9.
Chen J; Liu Y; Jia W; Xu X; Sun G; Wang T; Li J; Zhang G; Jing R; Sun H; Xu Y; Liu Y
Microbiol Spectr; 2023 Jun; 11(3):e0487322. PubMed ID: 37184411
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
[TBL] [Abstract][Full Text] [Related]
12. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
Sun S; Chen K; Kong X; Tian W; Niu S
Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
[TBL] [Abstract][Full Text] [Related]
13. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
14.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates.
Lim TP; Ho JY; Teo JQ; Sim JH; Tan SH; Tan TT; Kwa AL
Microorganisms; 2023 Aug; 11(9):. PubMed ID: 37764002
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
17. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
[TBL] [Abstract][Full Text] [Related]
18. Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and
Sader HS; Mendes RE; Kimbrough JH; Hubler CM; Castanheira M
Antibiotics (Basel); 2024 Jun; 13(6):. PubMed ID: 38927230
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
